Creating the conditions for universal access to new Hepatitis C treatments
Since 2014, the introduction of new Direct-Acting Antiviral (DAA) drugs has considerably changed the way hepatitis C infections are treated. These new highly-effective and well-tolerated treatments have enabled a sustained Lire la suite